[HTML][HTML] Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction

MV Polito, A Silverio, A Rispoli, G Vitulano, FD Auria… - Scientific Reports, 2020 - nature.com
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction

M Polito, A Silverio, A Rispoli, G Vitulano… - SCIENTIFIC …, 2020 - iris.unimol.it
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction

MV Polito, A Silverio, A Rispoli, G Vitulano… - Scientific …, 2020 - pubmed.ncbi.nlm.nih.gov
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

[HTML][HTML] Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction

MV Polito, A Silverio, A Rispoli, G Vitulano… - Scientific …, 2020 - ncbi.nlm.nih.gov
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction.

MV Polito, A Silverio, A Rispoli, G Vitulano… - Scientific …, 2020 - europepmc.org
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction.

MV Polito, A Silverio, A Rispoli, G Vitulano… - Scientific …, 2020 - search.ebscohost.com
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction

MV Polito, A Silverio, A Rispoli, G Vitulano… - Scientific …, 2020 - ui.adsabs.harvard.edu
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction

MV Polito, A Silverio, A Rispoli, G Vitulano… - SCIENTIFIC …, 2020 - iris.unina.it
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction

MV Polito, A Silverio, A Rispoli, G Vitulano… - SCIENTIFIC …, 2020 - iris.unisa.it
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction.

MV Polito, A Silverio, A Rispoli, G Vitulano… - Scientific …, 2020 - europepmc.org
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …